Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease

Yoshikuni Mizuno, Nobuo Yanagisawa, Sadako Kuno, Mitsutoshi Yamamoto, Kazuko Hasegawa, Hideki Origasa, Hisayuki Kowa, M. Tamaki, S. Simojyo, S. Koh, T. Maruyama, T. Kachi, M. Takahashi, T. Hazama, T. Matsubara, J. Kawamura, K. Hiyama, T. Nakamuro, T. Kondo, K. NakajimaK. Abe, Y. Sunada, T. Tuji, J. Yoshinaga, N. Yamashita, T. Yamada, H. Fukunaga, F. Moriwaka, M. Baba, I. Toyoshima, T. Abe, T. Yamamoto, K. Yamane, F. Yokochi, S. Nogawa, T. Simizu, M. Murata, Y. Mizuno, H. Oka

Research output: Contribution to journalArticlepeer-review

64 Citations (Scopus)

Abstract

We compared the efficacy and safety of pramipexole (PPX) with placebo in the treatment of advanced Parkinson's disease (PD) as an adjunct to levodopa. A bromocriptine (BR) group was included to enable determination of the noninferiority of PPX relative to BR as the standard treatment.

Original languageEnglish
Pages (from-to)1149-1156
Number of pages8
JournalMovement Disorders
Volume18
Issue number10
DOIs
Publication statusPublished - Oct 2003

Keywords

  • Bromocriptine
  • Drug comparison
  • Levodopa
  • Parkinson's disease
  • Pramipexole
  • Randomized controlled trial (RCT)

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease'. Together they form a unique fingerprint.

Cite this